Clinical trial · Observational
Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL)
Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia
NCT03035344CI-TRIAL-00025685unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study of the intermediate metabolism in children diagnosed with ALL compared to healthy matched controls.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia, Pediatric | Childhood Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| Metabolism Disorder | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metabolome study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- ALL paediatric patients
- description
- Metabolome study in children diagnosed with ALL after bone marrow biopsy
- interventionNames
- Other: Metabolome study
- label
- Healthy matched controls
- description
- Metabolome study in healthy children matched for gender and age with the patients group
- interventionNames
- Other: Metabolome study
Primary outcomes (1)
- measure
- Difference in measurement of aminoacids and organic acids between ALL patients and healthy matched controls.
- timeFrame
- Up to six months
- description
- The title of aminoacids in blood and urine and of organic acids in urine will be measured through Tandem Mass Spectrometry
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Month
- Maximum age
- 16 Years
Show eligibility criteria text
* Sex: all * Minimum age: 1 year * Maximum age: 16 years * The study accepts healthy volunteers as matched controls for the patinets. * Inclusion criteria: 1)Children diagnosed with ALL 2) Diagnosis confirmed with bone marrow biopsy 3) Sampling before the initiation of therapy 4) Informed consent signed * Exclusion Criteria: 1) Children with a known chronic illness before ALL diagnosis 2) ALL remission 3) Not signed informed consent * Population description: Patients are recruited from the Pediatric Hematology/Oncology Department of Aristotle University of Thessaloniki (AHEPA hospital) and from the Pediatric Hematology/ Oncology Department of Ippokration Hospital, that host all children diagnosed with ALL in nothern Greece. Matched controls are recruited from outpatient clinic of the 2nd and 4th Pediatric Department of Aristotle University of Thessaloniki. * Sampling method: Non-probability sample
References
Publications (0)
Data not yet available
No reference posted for this study.